Yalcin Koray, Ovali Ercument, Ozdamarlar Umut, Celen Suna, Karasu Gulsun, Yesilipek Akif, Hazar Volkan
Pediatric Hematology/Oncology and Stem Cell Transplantation Department, Medical Park Goztepe Hospital, Istanbul, Turkey.
Acibadem Labcell Cellular Therapy Center, Istanbul, Turkey.
Int Cancer Conf J. 2020 Mar 24;9(3):137-140. doi: 10.1007/s13691-020-00406-6. eCollection 2020 Jul.
Relapsed/refractory Ewing sarcoma prognosis is dreadful, especially for recurrences within the first 2 years after initial diagnosis. It is obvious that there is an urgent need for novel treatment strategies for this dismal situation. NK-92 is an activated NK cell line with high cytotoxicity against malignant cells. Here, we present a relapsed/refractory Ewing sarcoma case who had no response to conventional strategies and recieved intratumoral NK-92 cell injections. We observe that intratumoral injection of NK-92 is safe, has no toxicity and shows preliminary evidence of tumor response in relapsed/refractory Ewing Sarcoma.
复发性/难治性尤因肉瘤的预后很差，尤其是在初次诊断后的头两年内复发的情况。显然，对于这种严峻的情况，迫切需要新的治疗策略。NK-92是一种对恶性细胞具有高细胞毒性的活化自然杀伤细胞系。在此，我们报告一例复发性/难治性尤因肉瘤病例，该病例对传统治疗策略无反应，接受了瘤内注射NK-92细胞治疗。我们观察到，瘤内注射NK-92是安全的，没有毒性，并且在复发性/难治性尤因肉瘤中显示出肿瘤反应的初步证据。
